Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study

Because of the difficulty of conducting efficacy trials of vaccines against group B streptococcus (GBS), the licensure of these vaccines may have to rely on studies that measure vaccine-induced antibody levels that correlate with protection. This study estimates the level of maternal antibody requir...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The Journal of infectious diseases Ročník 184; číslo 8; s. 1022
Hlavní autoři:	Lin, F Y, Philips, 3rd, J B, Azimi, P H, Weisman, L E, Clark, P, Rhoads, G G, Regan, J, Concepcion, N F, Frasch, C E, Troendle, J, Brenner, R A, Gray, B M, Bhushan, R, Fitzgerald, G, Moyer, P, Clemens, J D
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 15.10.2001
Témata:	Age of Onset Antibodies, Bacterial - blood Female Fetal Blood - immunology Humans Immunity, Maternally-Acquired Immunoglobulin G - blood Infant, Newborn Predictive Value of Tests Pregnancy Pregnancy Complications - immunology Streptococcal Infections - immunology Streptococcal Infections - prevention & control Streptococcus agalactiae - immunology
ISSN:	0022-1899
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Because of the difficulty of conducting efficacy trials of vaccines against group B streptococcus (GBS), the licensure of these vaccines may have to rely on studies that measure vaccine-induced antibody levels that correlate with protection. This study estimates the level of maternal antibody required to protect neonates against early-onset disease (EOD) caused by GBS type Ia. Levels of maternal serum IgG GBS Ia antibodies, measured by ELISAs in 45 case patients (neonates with EOD caused by GBS Ia) and in 319 control subjects (neonates colonized by GBS Ia but without EOD) born at > or =34 weeks gestation were compared. The probability of developing EOD declined with increasing maternal levels of IgG GBS Ia antibody (P = .03). Neonates whose mothers had levels of IgG GBS Ia antibody > or =5 microg/mL had an 88% lower risk (95% confidence interval, 7%-98%) of developing type-specific EOD, compared with those whose mothers had levels < 0.5 microg/mL. A vaccine that induces IgG GBS Ia antibody levels > or =5 microg/mL in mothers can be predicted to confer a high degree of type-specific immunity to EOD to their infants.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0022-1899
DOI:	10.1086/323350